Home > Insider Trading > Filing (0001012975-17-000195)

Filing Details

Accession Number:: 0001012975-17-000195
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-07 16:35:15
Reporting Period:: 2017-03-03

Filing Date:: 2017-03-07
Accepted Time:: 2017-03-07 16:35:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219042	Robert Nelsen	C/O Arch Venture Partners 8755 West Higgins Road, Suite 1025 Chicago IL 60631		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-03-03	31,425	$50.69	9,174	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
Common Stock	Disposition	2017-03-03	8,734	$51.34	440	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
Common Stock	Disposition	2017-03-03	400	$52.15	40	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
Common Stock	Disposition	2017-03-06	40	$49.43	0	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	109,230	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.02 to $51.02. The reporting person undertakes to provide to AGIO, any security holder of AGIO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.03 to $51.98.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.27.
These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.